Observational studyJAMA network open2021
Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.
Observational study in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Cancer therapy-related cognitive impairment, part 1: an integrative clinical-mechanistic framework from phenotypes to convergent neurobiological pathways.Pharmacological reports : PR · 2026Review
- Post-Marketing Requirements for Anticancer Drugs Approved in Japan, 2001-2024: A Cross-Sectional Analysis.CPT: pharmacometrics & systems pharmacology · 2026Article
- Bringing the Teaching Close to Home: Implementation of a Near-Peer Model for Introductory Hematology-Oncology Fellowship Lecture Series.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Article
- Monotherapy cancer drug-blind response prediction is limited to intraclass generalization.PLoS computational biology · 2026Article
- Article
- A Review of 3D-Printed Medical Devices for Cancer Radiation Therapy.Bioengineering (Basel, Switzerland) · 2026Review
- Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy.JAMA network open · 2026Article
- Triazole-based hybrid molecules in anticancer drug discovery: structural classes and mechanistic insights, 2014-2025.Beilstein journal of organic chemistry · 2026Review
- Health Care Contact Days in Older Adults With Metastatic Cancer.JAMA network open · 2025Article
- Discovery and development of steroidal enzyme inhibitors as anti-cancer drugs: state-of-the-art and future perspectives.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- The effect of platinum nanoparticles on the physicochemical properties of daunorubicin.RSC advances · 2025Article
- Bisabolol as a natural anticancer agent: molecular insights and therapeutic potential in oncology.Medical oncology (Northwood, London, England) · 2025Review
- Oncolytic viruses targeting CD47: a new road to success?Journal for immunotherapy of cancer · 2025Review
- Development and optimization of Eva1 (Journal for immunotherapy of cancer · 2025Article
- Identification of a Selective Anticancer Agent from a Collection of Complex-And-Diverse Compounds Synthesized from Stevioside.Journal of the American Chemical Society · 2025Article
- Molecular docking, molecular dynamics simulation, and ADME profiling of novel benzoxazolone-based OGT inhibitors.In silico pharmacology · 2025Article
- Substantial Increase in the Costs of Antineoplastic Agents in the USA from 2010 to 2021.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Novel Systemic Anticancer Therapy and Healthcare Utilization at the End of Life: A Retrospective Cohort Study.Cancer medicine · 2024Article
- Pursuing Polypharmacology: Benzothiopyranoindoles as G-Quadruplex Stabilizers and Topoisomerase I Inhibitors for Effective Anticancer Strategies.ACS medicinal chemistry letters · 2024Article
- TLR-4: a promising target for chemotherapy-induced peripheral neuropathy.Molecular biology reports · 2024Review
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Both novel and next-in-class cancer drugs have a role in oncology, but the relative development of each is understudied. Objective: To characterize the mechanisms of action of anticancer drugs approved by the US Food and Drug Administration (FDA) between 2009 and 2020, noting how many approvals were based on a new mechanism of action vs next-in-class approvals. Design, Study, and Participants: This cross-sectional study included all anticancer drugs approved by the FDA from January 2009 to December 2020. The mechanism of action of each drug was extracted from FDA labels. Supportive-care treatments were excluded. Exposures: Name of drug approved, date of approval, indication, tumor type, mechanism of action, broad pharmaceutical class, and biological target. Approvals considering all tumor types and each tumor type separately were classified in 3 nonoverlapping categories: new mechanism of action, next in class, or subsequent approval. Main Outcomes and Measures: The number of all approvals each year; the number of approvals based on a new mechanism of action, either by drug (considering all tumor types) or by indication (considering tumor types separately); and the frequency of these numbers over time. Results: Overall, 332 approvals were included. Between 2009 and 2020, there was an increase in the total number of approvals from 8 to 57. We found that 209 approvals (63%) were for a next-in-class indication in a new tumor type (84 [25%]) or a subsequent indication of the same drug in the same tumor type (195 [59%]). When considering each tumor type separately, 123 approvals (37%) were based on a new mechanism of action. Conclusions and Relevance: In this study, approvals based on a new mechanism of action represented a minority of all approvals. Further consideration of incentives for drug development are needed to prioritize novel or highly innovative and transformative anticancer drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.